Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease

Background/aims The aim of this study was to assess the effect of functional ENPP1(ectoenzyme nucleotide pyrophosphate phosphodiesterase 1)/PC-1 (plasma cell antigen-1) and IRS-1 (insulin receptor substrate-1) polymorphisms influencing insulin receptor activity on liver damage in non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, whose progression is associated with the severity of insulin resistance. Patients and methods 702 patients with biopsy-proven NAFLD from Italy and the UK, and 310 healthy controls. The Lys121Gln ENPP1/PC-1 and the Gly972Arg IRS-1 polymorphisms were evaluated by restriction analysis. Fibrosis was evaluated according to Kleiner. Insulin signalling activity was evaluated by measuring phosphoAKT levels by western blotting in a subset of obese non-diabetic patients. Results The ENPP1 121Gln and IRS-1 972Arg polymorphisms were detected in 28.7% and 18.1% of patients and associated with increased body weight/dyslipidaemia and diabetes risk, respectively. The ENPP1 121Gln allele was significantly associated with increased prevalence of fibrosis stage >1 and >2, which was higher in subjects also positive for the 972Arg IRS-1 polymorphism. At multivariate analysis, the presence of the ENPP1 121Gln and IRS-1 972Arg polymorphisms was independently associated with fibrosis >1 (OR 1.55, 95% CI 1.24 to 1.97; and OR 1.57, 95% CI 1.12 to 2.23, respectively). Both polymorphisms were associated with a marked reduction of ∼70% of AKT activation status, reflecting insulin resistance and disease severity, in obese patients with NAFLD. Conclusions The ENPP1 121Gln and IRS-1 972Arg polymorphisms affecting insulin receptor activity predispose to liver damage and decrease hepatic insulin signalling in patients with NAFLD. Defective insulin signalling may play a causal role in the progression of liver damage in NAFLD.

[1]  Amit R. Indap,et al.  Genes mirror geography within Europe , 2008, Nature.

[2]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[3]  L. N. Valenti,et al.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.

[4]  S. Friedman,et al.  The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[5]  G. Sesti,et al.  Transgenic mice overexpressing human G972R IRS-1 show impaired insulin action and insulin secretion. , 2008, Journal of cellular and molecular medicine.

[6]  D. Accili,et al.  The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. , 2008, Endocrine reviews.

[7]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[8]  S. Pocock,et al.  Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.

[9]  L. N. Valenti,et al.  Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis , 2007, Diabetes.

[10]  V. Stefanović,et al.  The association of PC-1 (ENPP1) K121Q polymorphism with metabolic syndrome in patients with coronary heart disease. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[11]  C. Day,et al.  Genetics of Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease , 2007, Seminars in liver disease.

[12]  V. Trischitta,et al.  The Pleiotropic Effect of the ENPP1 (PC-1) Gene on Insulin Resistance, Obesity, and Type 2 Diabetes , 2006 .

[13]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.

[14]  M. McCarthy,et al.  No Evidence of Association of ENPP1 Variants With Type 2 Diabetes or Obesity in a Study of 8,089 U.K. Caucasians , 2006, Diabetes.

[15]  R. Ceriani,et al.  α1‐Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage , 2006, Hepatology.

[16]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[17]  T. Hansen,et al.  Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects , 2006, Diabetologia.

[18]  Lisa M Yerian,et al.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.

[19]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[20]  C. Kahn,et al.  Human Insulin Receptor Substrate-1 (IRS-1) Polymorphism G972R Causes IRS-1 to Associate with the Insulin Receptor and Inhibit Receptor Autophosphorylation* , 2005, Journal of Biological Chemistry.

[21]  A. Suzuki,et al.  Chronological development of elevated aminotransferases in a nonalcoholic population , 2005, Hepatology.

[22]  M. Benito,et al.  IRS‐2 mediates the antiapoptotic effect of insulin in neonatal hepatocytes , 2004, Hepatology.

[23]  M. McCarthy,et al.  Association studies of insulin receptor substrate 1 gene (IRS1) variants in type 2 diabetes samples enriched for family history and early age of onset. , 2004, Diabetes.

[24]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[25]  A. Gnasso,et al.  The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. , 2004, Diabetes care.

[26]  D. Accili,et al.  FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation , 2004, Cell.

[27]  E. Feskens,et al.  Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies , 2003, Diabetologia.

[28]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[29]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[30]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[31]  C. Kahn,et al.  Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. , 2000, Molecular cell.

[32]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.

[33]  G Scarlato,et al.  A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. , 1999, Diabetes.

[34]  C. Day.  From fat to inflammation. , 2006, Gastroenterology.

[35]  Tx Southwestern.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2005 .

[36]  L. N. Valenti,et al.  Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. , 2002, Gastroenterology.